Research & Development
Explore Life Science, Innovate Cancer Precision Therapy
APS is going to launch a China only Phase I clinical trial
A Phase I, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of APS03118 in Adult Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Harboring RET Mutations or Fusions

The purpose of this trial was to explore the safety, efficacy and pharmacokinetic characteristics of APS03118 in patients in China with advanced non-small cell lung cancer (NSCLC), medullary thyroid cancer(MTC), and other solid tumors with RET mutation or fusion.


Contact

Address

Office: Philadelphia, US

Office: Building 10-1, No.2 Jingyuan North Street, BDA, Beijing, China

Tel

+1-484-222-1342 +86-10-67860673

Mobile Mode
Copyright © 2022 All Rights Reserved Applied Pharmaceutical Science
Terms of Use

Loading...

Privacy policy

Loading...